Skip to Main content Skip to Navigation
Journal articles

Assessing the cost-effectiveness of hepatitis C screening strategies in France

Abstract : BACKGROUND & AIMS: In Europe, hepatitis C virus (HCV) screening still targets people at high risk of infection. We aim to determine the cost-effectiveness of expanded HCV screening in France. METHODS: A Markov model simulated chronic hepatitis C (CHC) prevalence, incidence of events, quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratio (ICER) in the French general population, aged 18 to 80 years, undiagnosed for CHC for different strategies: S1 = current strategy targeting the at risk population; S2 = S1 and all men between 18 and 59 years; S3 = S1 and all individuals between 40 and 59 years; S4 = S1 and all individuals between 40 and 80 years; S5 = all individuals between 18 and 80 years (universal screening). Once CHC was diagnosed, treatment was initiated either to patients with fibrosis stage ≥F2 or regardless of fibrosis. Data were extracted from published literature, a national prevalence survey, and a previously published mathematical model. ICER were interpreted based on one or three times French GDP per capita (€32,800). RESULTS: Universal screening led to the lowest prevalence of CHC and incidence of events, regardless of treatment initiation. When considering treatment initiation to patients with fibrosis ≥F2, targeting all people aged 40-80 was the only cost-effective strategy at both thresholds (€26,100/QALY). When we considered treatment for all, although universal screening of all individuals aged 18-80 is associated with the highest costs, it is more effective than targeting all people aged 40-80, and cost-effective at both thresholds (€31,100/QALY). CONCLUSIONS: In France, universal screening is the most effective screening strategy for HCV. Universal screening is cost-effective when treatment is initiated regardless of fibrosis stage. From an individual and especially from a societal perspective of HCV eradication, this strategy should be implemented. LAY SUMMARY: In the context of highly effective and well tolerated therapies for hepatitis C virus that are now recommended for all patients, a reassessment of hepatitis C screening strategies is needed. An effectiveness and cost-effectiveness study of different strategies targeting either the at-risk population, specific ages or all individuals was performed. In France, universal screening is the most effective strategy and is cost-effective when treatment is initiated regardless of fibrosis stage. From an individual and especially from a societal perspective of hepatitis C virus eradication, this strategy should be implemented.
Document type :
Journal articles
Complete list of metadatas

Cited literature [76 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02472188
Contributor : Sylvie Deuffic-Burban <>
Submitted on : Monday, February 10, 2020 - 9:42:13 AM
Last modification on : Thursday, June 4, 2020 - 4:24:07 PM
Document(s) archivé(s) le : Monday, May 11, 2020 - 1:24:03 PM

File

ManuscriptAndSuppl_JHEP.pdf
Files produced by the author(s)

Identifiers

Citation

Sylvie Deuffic-Burban, Alexandre Huneau, Adeline Verleene, Cécile Brouard, Josiane Pillonel, et al.. Assessing the cost-effectiveness of hepatitis C screening strategies in France. Journal of Hepatology, Elsevier, 2018, 69 (4), pp.785-792. ⟨10.1016/j.jhep.2018.05.027⟩. ⟨inserm-02472188⟩

Share

Metrics

Record views

286

Files downloads

623